JB Chemicals & Pharmaceuticals Ltd

NSE: JBCHEPHARMBSE: 506943

P/E: 53.9x
ROE: 19%
ROCE: 25%
Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Listed on: NSE, BSE

Quick check

The five things to look at first. Open one for more.

Compared with its industry

JB Chemicals & Pharmaceuticals Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

Valuation (P/E)53.9 against a typical 34.3: pricier than most peers (1st = cheapest).162nd of 220
Sales growth−4.7% against a typical +15.6% from a year earlier.157th of 197
Profit growth−30.8% against a typical +18.9% from a year earlier.120th of 160

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

High safety

Rated AA+ by CRISIL

AA+

DefaultRiskyModerateSafeVery safe

No warnings from the agency.

Agency	Current rating	Outlook	As of
CRISIL	Crisil AA+	Stable	17 Mar 2026

Credit rating actions
		Rating
17 Mar 2026	▲ Upgrade1 notch	Crisil AA/Watch Developing → Crisil AA+	—	CRISIL	₹ 379 Cr.
31 Dec 2025	Reaffirmed	Crisil AA/Watch Developing	—	CRISIL	₹ 379 Cr.
3 Oct 2025	Reaffirmed	Crisil AA/Watch Developing	—	CRISIL	₹ 379 Cr.

Board meetings

Results dates and other board meetings. Full calendar

		Details
11 May 2026	Financial Results/Dividend	To consider and approve the financial results for the period ended March 31, 2026 and dividend
5 Feb 2026	Dividend	This is to intimate you that meeting of the Board of Directors of the Company will be held on February 5, 2026, inter alia, to consider declaration of Interim dividend, if any, for the financial year 2025-26.
16 Jan 2026	Financial Results	To consider and approve the unaudited financial results for the quarter and nine months ending December 31, 2025
11 Nov 2025	Financial Results	To consider and approve the unaudited financial results for the period ended September 30, 2025
30 Jul 2025	Financial Results	To consider and approve the unaudited financial results for the period ended Jun 30, 2025
14 May 2025	Financial Results/Dividend	To consider and approve the financial results for the quarter and year ended on March 31, 2025 and to consider and recommend dividend on equity shares of the Company, if any, subject to approval of the shareholders

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	896	882	845	862	1,004	1,001	963	949	1,094	1,085	1,065	904
Expenses	664	638	621	664	724	730	709	723	793	775	769	703
Operating Profit	232	244	223	198	280	271	255	226	301	310	296	201
OPM %	26%	28%	26%	23%	28%	27%	26%	24%	28%	29%	28%	22%
Other Income	6	8	7	17	6	10	8	14	15	15	18	−15
Interest	12	10	12	9	6	2	3	1	1	1	2	1
Depreciation	31	32	34	41	41	42	42	46	43	44	45	50
Profit before tax	194	209	184	165	240	237	218	193	272	279	267	135
Tax %	27%	28%	27%	23%	26%	26%	25%	25%	25%	26%	26%	25%
Net Profit	142	151	134	126	177	175	162	146	202	208	198	101
EPS in Rs	9.19	9.72	8.62	8.13	11.39	11.24	10.45	9.36	12.96	13.27	12.63	6.31

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth

10 Years: 13%
5 Years: 15%
3 Years: 10%
TTM: 6%

Compounded Profit Growth

10 Years: 18%
5 Years: 12%
3 Years: 21%
TTM: 15%

Stock Price CAGR

10 Years: 33%
5 Years: 23%
3 Years: 22%
TTM: —

Return on Equity

10 Years: 18%
5 Years: 19%
3 Years: 19%
TTM: —

Shareholding

Latest: Mar 2026.

Promoters

48.8%

+0.96 pts in a year

FIIs

16.33%

−1.97 pts in a year

DIIs

21.38%

+2.67 pts in a year

Government

0 pts in a year

Public

13.48%

−1.65 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 53.9xEPS (12 months) ₹ 44.74Median P/E 20.9x

P/E (times)EPS (₹)

Prices are delayed and for information only. Nothing on this page is investment advice.